Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/tazobactam vs meropenem in ventilated nosocomial pneumonia (Phase 3)
KCT0001273Phase 3Completed
- Sponsor
- Cubist Pharmaceuticals, Inc.
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceftolozane + tazobactam in ventilator-associated pneumonia (VAP), hospital-acquired pneumonia (HAP), sponsored by Cubist Pharmaceuticals, Inc.. Started Jan 2015; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
ventilator-associated pneumonia (VAP)hospital-acquired pneumonia (HAP)
Beyond the preview
Go deeper on KCT0001273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001273.